type C decompensated cirrhosis
Conditions
Interventions
None listed
Sponsors
Nippon Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Cases of introducing Sofosbuvir / Velpatasvir combination therapy for type C decompensated cirrhosis (2)Age: 18 years old or older (3)Gender: No matter what (4)Hospitalization / outpatient: no question
Exclusion criteria
Exclusion criteria: (1)Patients with a history of hypersensitivity to the ingredients of this drug (2)Patients with severe renal dysfunction (eGFR <30 mL / min / 1.73m2) or renal failure requiring dialysis (3)Patients taking the following drugs Foods containing carbamazepine, phenytoin, phenobarbital, rifampicin, hypericum (St. John's wort) (4)Patient who is pregnant or breastfeeding (5)Patients with hepatocellular carcinoma and other cancers (6)patients who are judged to be inappropriate for participation in the study by the study doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SVR12 rate (Percent of patients with negative HCV RNA 12 weeks after the end of treatment) | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Patient background: age, sex, height, weight, complications, medical history (2) Subjective symptoms (3) Presence or absence of liver-related complications: hepatic edema, hepatic encephalopathy, esophageal / gastric varices (4) Clinical laboratory items | — |
Countries
Japan
Contacts
Public ContactHayama Korenobu
Nippon Medical School Division of Gastroenterology and Hepatology, Department of Internal Medicine
Outcome results
None listed